Saltar al contenido
Merck
  • GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.

GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.

Scientific reports (2017-09-28)
Masayuki Amano, Pedro Miguel Salcedo-Gómez, Ravikiran S Yedidi, Nicole S Delino, Hirotomo Nakata, Kalapala Venkateswara Rao, Arun K Ghosh, Hiroaki Mitsuya
RESUMEN

We report that GRL-09510, a novel HIV-1 protease inhibitor (PI) containing a newly-generated P2-crown-tetrahydrofuranylurethane (Crwn-THF), a P2'-methoxybenzene, and a sulfonamide isostere, is highly active against laboratory and primary clinical HIV-1 isolates (EC

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Atazanavir, ≥98% (HPLC)
Sigma-Aldrich
Amprenavir, ≥98% (HPLC)